Quality by Design (QbD) in Nanoformulation Development: Current Status and Future Perspectives, A Comprehensive Review

Original Research | 2026 | Volume 1 | Issue 2 | Page 139-160

¹Ms Sakshi Chauhan,²Ms Manvi,³Ms Nisha,⁴Mr Sachin Sharma

¹Assistant Professor,ITS College of Pharmacy,Muradnagar,Ghaziabad

² Assistant Professor,ITS College of Pharmacy,Muradnagar,Ghaziabad

³Assistant Professor,ITS College of Pharmacy,Muradnagar,Ghaziabad

⁴Assistant Professor,ITS College of Pharmacy,Muradnagar,Ghaziabad

Quality by Design (QbD) in Nanoformulation Development: Current Status and Future Perspect.

Download • 656KB

Abstract

Nanoformulations — including liposomes, polymeric nanoparticles, lipid nanoparticles (LNPs), solid lipid nanoparticles/nanostructured lipid carriers (SLNs/NLCs), nanocrystals, polymeric micelles, dendrimers, and nanoemulsions — have transformed drug delivery by improving solubility, bioavailability, targeting, and controlled release of therapeutics. Despite these advantages, the inherent structural complexity, multi-step manufacturing processes, and colloidal instability of nanocarriers create substantial challenges for reproducible, scalable, and regulator-ready production. Quality by Design (QbD), formalized through the International Council for Harmonization (ICH) Q8–Q11 and Q14 guidelines, offers a systematic, risk-based framework that shifts pharmaceutical development from empirical trial-and-error and end-product testing toward a proactive strategy built on process understanding and predefined quality objectives. This review synthesizes the current state of QbD implementation across major nanoformulation platforms, detailing the sequential application of the Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs), quality risk assessment tools (Ishikawa diagrams, Failure Mode and Effects Analysis), Design of Experiments (DoE), design space definition, and risk-based control strategies incorporating Process Analytical Technology (PAT) and real-time release testing (RTRT). Platform-specific case studies are examined for liposomes, PLGA and other polymeric nanoparticles, mRNA/siRNA-loaded LNPs, SLNs/NLCs, and drug nanocrystals, alongside regulatory milestones represented by Doxil, Abraxane, Onpattro, and the mRNA-LNP COVID-19 vaccines. The review further discusses emerging trends, including the integration of artificial intelligence and machine learning into QbD workflows, microfluidic and continuous-flow manufacturing, and evolving regulatory expectations for nanomaterial-containing drug products. Persistent challenges — analytical characterization limitations, scale-up variability, and the absence of harmonized nanospecific regulatory pathways — are critically appraised, and future directions toward fully digitalized, model-informed, and continuously verified nanomanufacturing are proposed.

Keywords: Quality by Design; nanoformulation; nanomedicine; Critical Quality Attributes; Design of Experiments; Process Analytical Technology; lipid nanoparticles; liposomes; regulatory science; machine learning.